Abstract：
UNASSIGNED: Acute myeloid leukemia (AML) with t(8;21) manifests as a diverse hematological malignancy. Although it was categorized into a favorable subtype, 30-40% of patients experience relapse. The objective of this research was to devise a nomogram for the accurate anticipation of both overall survival (OS) and cancer-specific survival (CSS) in t(8;21) AML.
UNASSIGNED: From the Surveillance, Epidemiology, and End Results (SEER) database, individuals diagnosed with t(8;21) AML from 2000 to 2018 were selected. Prognostic factors for t(8;21) AML were identified using Cox regression analysis and Akaike Information Criterion (AIC), forming the basis for constructing prognostic nomograms.
UNASSIGNED: Key variables, including first primary tumor, age group, race, and chemotherapy, were identified and integrated into the nomogram. The C-index values for the nomograms predicting OS and CSS were 0.753 (validation: 0.765) and 0.764 (validation: 0.757), respectively. Ultimately, based on nomogram scores, patients were stratified into high-risk and low-risk groups, revealing significant disparities in both OS and CSS between these groups (P < 0.001).
UNASSIGNED: This study innovatively crafted nomograms, incorporating clinical and therapeutic variables, to forecast the 1-, 3-, and 5-year survival rates for individuals with t(8;21) AML.
UNASSIGNED: From the Surveillance, Epidemiology, and End Results (SEER) database, individuals diagnosed with t(8;21) AML from 2000 to 2018 were selected. Prognostic factors for t(8;21) AML were identified using Cox regression analysis and Akaike Information Criterion (AIC), forming the basis for constructing prognostic nomograms.
UNASSIGNED: Key variables, including first primary tumor, age group, race, and chemotherapy, were identified and integrated into the nomogram. The C-index values for the nomograms predicting OS and CSS were 0.753 (validation: 0.765) and 0.764 (validation: 0.757), respectively. Ultimately, based on nomogram scores, patients were stratified into high-risk and low-risk groups, revealing significant disparities in both OS and CSS between these groups (P < 0.001).
UNASSIGNED: This study innovatively crafted nomograms, incorporating clinical and therapeutic variables, to forecast the 1-, 3-, and 5-year survival rates for individuals with t(8;21) AML.
摘要：
■急性髓性白血病(AML)伴t(8;21)表现为多种血液恶性肿瘤。虽然它被归类为一个有利的亚型，30-40%的患者经历复发。这项研究的目的是设计一个列线图，用于准确预测t（8;21）AML的总体生存率（OS）和癌症特异性生存率（CSS）。
■来自监视，流行病学,和最终结果(SEER)数据库，选择2000年至2018年诊断为t（8;21）AML的个体。t(8;21)AML的预后因素使用Cox回归分析和Akaike信息标准(AIC)进行鉴定，形成构建预后列线图的基础。
■关键变量，包括第一原发肿瘤,年龄组,种族,和化疗，被识别并整合到列线图中。预测OS和CSS的列线图的C指数值为0.753（验证：0.765）和0.764（验证：0.757），分别。最终,根据列线图分数，患者分为高危和低危，揭示了这些组间OS和CSS的显著差异(P<0.001)。
■这项研究创新性地制作了列线图，结合临床和治疗变量，预测1-，3-,t(8;21)AML患者的5年生存率。
■来自监视，流行病学,和最终结果(SEER)数据库，选择2000年至2018年诊断为t（8;21）AML的个体。t(8;21)AML的预后因素使用Cox回归分析和Akaike信息标准(AIC)进行鉴定，形成构建预后列线图的基础。
■关键变量，包括第一原发肿瘤,年龄组,种族,和化疗，被识别并整合到列线图中。预测OS和CSS的列线图的C指数值为0.753（验证：0.765）和0.764（验证：0.757），分别。最终,根据列线图分数，患者分为高危和低危，揭示了这些组间OS和CSS的显著差异(P<0.001)。
■这项研究创新性地制作了列线图，结合临床和治疗变量，预测1-，3-,t(8;21)AML患者的5年生存率。
